A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.

PHASE3CompletedINTERVENTIONAL
Enrollment

2,646

Participants

Timeline

Start Date

February 3, 2022

Primary Completion Date

March 3, 2022

Study Completion Date

March 3, 2023

Conditions
COVID-19SARS-CoV-2 Acute Respiratory Disease
Interventions
BIOLOGICAL

COVID-19 Vaccine 40 ug/dose

Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V

Trial Locations (18)

17007

Hospital Universitari Dr. Josep Trueta, Girona

17170

Hospital Clinic de Barcelona, Barcelona

20162

Hospital de Niguarda, Milan

28007

Hospital Gregorio Marañón, Madrid

28046

Hospital Universitario La Paz, Madrid

28050

Hospital HM Sanchinarro, Madrid

28223

Hospital Quironsalud Madrid, Madrid

28660

Hospital HM Montepríncipe, Madrid

28805

Hospital Principe de Asturias, Meco

28938

Hospital HM Puerta del Sur, Móstoles

29010

Hospital Regional Universitario de Málaga, Málaga

46010

Hospital Clínico de Valencia, Valencia

48903

Hospital de Cruces, Barakaldo

08916

Hospital Germans Trias I Pujol, Badalona

08100

Hospital de Mollet, Mollet del Vallès

08023

Hospital HM Delfos, Barcelona

Hospital Quironsalud Barcelona, Barcelona

08035

Hospital Vall Hebron, Barcelona

Sponsors
All Listed Sponsors
lead

Hipra Scientific, S.L.U

INDUSTRY

NCT05246137 - A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19. | Biotech Hunter | Biotech Hunter